Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Repligen's price to sales ratio was 12.4× on Nov 11, 2026, against 13.6× a year earlier. Over the last 5 years it ranged from 9.0× to 24.7×, with a median of 12.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 12.4× | −0.6 |
| 2025 | Dec 31, 2025 | 13.0× | +0.3 |
| 2024 | Dec 31, 2024 | 12.7× | −2.6 |
| 2023 | Dec 29, 2023 | 15.4× | +3.6 |
| 2022 | Dec 30, 2022 | 11.7× | −13.0 |
| 2021 | Dec 31, 2021 | 24.7× | −6.1 |
| 2020 | Dec 31, 2020 | 30.8× | +11.8 |
| 2019 | Dec 31, 2019 | 19.1× | +6.5 |
| 2018 | Dec 31, 2018 | 12.6× | −0.0 |
| 2017 | Dec 29, 2017 | 12.6× | +2.2 |
| 2016 | Dec 30, 2016 | 10.4× | −1.5 |
| 2015 | Dec 31, 2015 | 11.9× | +1.5 |
| 2014 | Dec 31, 2014 | 10.4× | −5.6 |
| 2013 | Dec 31, 2013 | 15.9× | +8.8 |
| 2012 | Dec 31, 2012 | 7.1× | +3.2 |
| 2011 | Dec 30, 2011 | 3.9× | −3.0 |
| 2010 | Dec 31, 2010 | 6.9× | – |
See a number that looks wrong?